Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Whalewatcher1 when you're going for the jugular don't miss!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(13)
•••
Comment by C10H12N2on Dec 27, 2021 9:21pm
96 Views
Post# 34264769

RE:RE:Whalewatcher1 when you're going for the jugular don't miss!

RE:RE:Whalewatcher1 when you're going for the jugular don't miss!Having given the Nasdaq guidelines another read - Algernon has even better uplisting route under the "Equity sdtandard' of PAGE 11 of the guidelines.

Nasdaq Initial Listing Guide 

There's a requirement of $15 million USD "Market Value of Unrestricted Publicly Held Shares" 

The $15 million valuation would be satisfied with an IPO of $9 per share based on the current outstanding shares ($15 million USD ÷ 1,674,868 = $8.96 USD).

I believe they should IPO for no less than $30 USD per share.

$50M USD minimum market cap.

$10M USD capital raise.

2 million shares total outstanding.

Anything less than $30 USD IPO and/or dilution above 2M outstanding will further cut shareholders to the core before any positive catalysts from real world data. 

Run the Phase 1 clinical trials for DMT/Stroke and Ifenprodil/SCLC.

See what traction comes of that without selling off the company to chase "Chronic Cough"  AGAIN or attempting to launch a "real" Phase 2 clinical trial for IPF.

The market has heard ENOUGH BS about IPF and Chronic Cough since 2019.

MOVE ON MANAGEMENT >>> DMT & SCLC & A FRIGGIN PARTNER$HIP


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities